Melanoma is a common, aggressive malignancy characterized by genetic heterogeneity and resistance to therapy. To improve patient survival, new molecular targets and treatment strategies are needed. The long term goal of this proposal is to test the hypothesis that inhibiting the cancer-critical survival protein HSP70 constitutes an effective new strategy for melanoma therapy. The stress-inducible HSP70 molecular chaperone is an attractive target for several reasons: this protein is markedly overexpressed in melanomas relative to normal melanocytes, and considerable evidence points to the importance of the mulfi-functional HSP70 chaperone in promoting melanoma tumorigenesis. HSP70 plays a central role in maintaining protein quality control and promoting tumor cell survival in response to a variety of endogenous and exogenous stresses. We have identified and characterized a novel small molecule (2-phenylethynesulfonamide, or PES) that selectively binds to HSP70 and inhibits its function. Our studies demonstrate that PES is preferentially cytotoxic to melanoma tumor cells relative to non-transformed cells or primary melanocytes. In the proposed study, we will use biochemical and structural biology analyses to probe the mechanism of action of PES. We will perform a structure-activity relationship analysis for this compound, and pursue derivatives with enhanced cytotoxicity and HSP70-inhibition. We will elucidate genotype(s) of melanoma with particular sensitivity to PES, and assess potential synergy with other, melanoma relevant compounds. We will better elucidate the pathways of cytotoxicity, and define pathways of resistance. And finally, we will test the impact on HSP70 inhibition on melanoma initiation and progression, in transgenic and patient-derived xenograft models. Taken together, the integrated research plan takes advantage of the unique structural biology, chemistry, and mouse models expertise of the program Investigators in order to further develop an exciting new strategy for melanoma therapy. As such, the proposed investigations will begin to address a major unmet clinical need.
Melanoma is a major public health problem for which there are few effective treatment options. Because the HSP70 molecular chaperone promotes melanoma tumorigenesis through multiple signaling and protein quality control networks, it is recognized as a promising new target for therapy. The proposed research plan takes advantage of our recent identification of a novel class of small molecule HSP70 inhibitors to test a promising strategy for treating melanomas based on inhibiting this cancer-critical survival protein.
|Webster, Marie R; Xu, Mai; Kinzler, Kathryn A et al. (2015) Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell Melanoma Res 28:184-95|
|Leu, Julia I-Ju; Zhang, Pingfeng; Murphy, Maureen E et al. (2014) Structural basis for the inhibition of HSP70 and DnaK chaperones by small-molecule targeting of a C-terminal allosteric pocket. ACS Chem Biol 9:2508-16|
|Vultur, A; Villanueva, J; Krepler, C et al. (2014) MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene 33:1850-61|
|Streib, Manuel; Kraling, Katja; Richter, Kristin et al. (2014) An organometallic inhibitor for the human repair enzyme 7,8-dihydro-8-oxoguanosine triphosphatase. Angew Chem Int Ed Engl 53:305-9|
|Ma, Xiao-Hong; Piao, Sheng-Fu; Dey, Souvik et al. (2014) Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 124:1406-17|
|Zhang, Pingfeng; Leu, Julia I-Ju; Murphy, Maureen E et al. (2014) Crystal structure of the stress-inducible human heat shock protein 70 substrate-binding domain in complex with peptide substrate. PLoS One 9:e103518|
|Wang, Tao; Ge, Yingbin; Xiao, Min et al. (2014) SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. J Invest Dermatol 134:1108-18|
|Malecka, Kimberly A; Fera, Daniela; Schultz, David C et al. (2014) Identification and characterization of small molecule human papillomavirus E6 inhibitors. ACS Chem Biol 9:1603-12|
|Licciulli, Silvia; Maksimoska, Jasna; Zhou, Chun et al. (2013) FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. J Biol Chem 288:29105-14|
|Kastl, Anja; Dieckmann, Sandra; Wahler, Kathrin et al. (2013) Rhenium complexes with visible-light-induced anticancer activity. ChemMedChem 8:924-7|
Showing the most recent 10 out of 33 publications